• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc. (Amendment)

    2/14/23 4:34:39 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EGRX alert in real time by email
    SC 13G/A 1 tarriff_sc13ga-123122.htm AMENDMENT TO FOR SC 13G

     

     

     

     

     

     

    UNITED STATES

     

     

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

     

     

     

     

     

    Washington, D.C. 20549

     

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 8)*

     

    Eagle Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    269796108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    Rule 13d-1(b)

     

    ¨

     

    Rule 13d-1(c)

     

    x

     

    Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     
     

     

     

    CUSIP No. 269796108  13G   

     

     

     

    1

     

    Name of Reporting Persons
    I.R.S. Identification No. of Above Persons (Entities Only)

    Scott Tarriff

     
      2 Check the Appropriate Box if a Member of a Group* 
        (a)  ¨ 
        (b) x (1) 
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    United States
         

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

     

     

    5 Sole Voting Power
    1,364,473 (See Item 4 herein)
     

    6

     

    Shared Voting Power
    1,168,984 (See Item 4 herein)
     

    7

     

    Sole Dispositive Power
    1,364,473 (See Item 4 herein)
     

    8

     

    Shared Dispositive Power
    1,168,984 (See Item 4 herein)
     

     

     

    9

     

    Aggregate Amount Beneficially Owned by Each Reporting Person
    2,533,457 (See Item 4 herein)
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* ¨
     

     

     

    11

     

    Percent of Class Represented by Amount in Row (9)
    18.06% (See Item 4 herein)
     

     

     

    12

     

    Type of Reporting Person*
    IN
             

      

     

     

    (1) This Schedule 13G is filed by Scott Tarriff, Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 and Michael Graves (collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    2 
     

     

     

     CUSIP No. 269796108 13G  

     

     

     

    1

     

    Name of Reporting Persons
    I.R.S. Identification No. of Above Persons (Entities Only)

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016

     
      2 Check the Appropriate Box if a Member of a Group*
        (a) ¨
        (b) x (1)
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    New Jersey

     

           

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

     

     

    5 Sole Voting Power
    0 (See Item 4 herein)
       
    6 Shared Voting Power
    992,623 (See Item 4 herein)
       
    7 Sole Dispositive Power
    0 (See Item 4 herein)
       
    8 Shared Dispositive Power
    992,623 (See Item 4 herein)
             

     

     

     

    9

     

    Aggregate Amount Beneficially Owned by Each Reporting Person
    992,623 (See Item 4 herein)
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* ¨
     

     

     

    11

     

    Percent of Class Represented by Amount in Row (9)
    7.63% (See Item 4 herein)
     

     

     

    12

     

    Type of Reporting Person*
    OO

     

     

     

    (1) The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    3 
     

     

     

    CUSIP No. 269796108 13G  

     

     

     

    1

     

    Name of Reporting Persons
    I.R.S. Identification No. of Above Persons (Entities Only)

    Michael Graves

     
      2 Check the Appropriate Box if a Member of a Group*
        (a) ¨
        (b) x (1)
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

     

     

    5 Sole Voting Power
    124,740 (See Item 4 herein)
     
    6 Shared Voting Power
    992,623 (See Item 4 herein)
     
    7 Sole Dispositive Power
    124,740 (See Item 4 herein)
     
    8 Shared Dispositive Power
    992,623 (See Item 4 herein)

     

      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,117,363 (See Item 4 herein)
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* ¨
     
      11 Percent of Class Represented by Amount in Row (9)
    8.50% (See Item 4 herein)
     
      12 Type of Reporting Person*
    IN

      

      

     

    (1) The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    4 
     

     

     

    CUSIP No. 269796108   13G  

     

    Item 1.
      (a) Name of Issuer
    Eagle Pharmaceuticals, Inc.

     

     

    (b)

     

    Address of Issuer’s Principal Executive Offices
    50 Tice Boulevard, Suite 315

    Woodcliff Lake, NJ 07677 

     

    Item 2.

     

     

     

    (a)

     

    Name of Person Filing

    Scott Tarriff,

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016,

    Michael Graves

    (together, the “Reporting Persons”)

     

     

     

    (b)

     

     

    Address of Principal Business Office or, if none, Residence

    The address for the principal business office of Scott Tarriff is:

     

    c/o Eagle Pharmaceuticals, Inc.

    50 Tice Boulevard, Suite 315

    Woodcliff Lake, NJ 07677

     

    The address for the principal business office of the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 is:

     

    1246 University Avenue West

    Suite 463

    St. Paul, MN 55104

     

    The address for the residence of Michael Graves is:

     

    1246 University Avenue West

    Suite 463

    St. Paul, MN 55104

     

     

     

     

    (c)

     

     

    Citizenship

    Scott Tarriff - United States

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 – New Jersey

    Michael Graves - United States

     

     

     

    (d)

     

     

    Title of Class of Securities
    Common Stock, $0.001 par value per share (the “Common Stock”)

     

     

     

    (e)

     

     

    CUSIP Number
    269796108

     

     

    5 
     

      

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  
      Not applicable
       
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨  Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________.

     

     

    6 
     

     

     

    CUSIP No. 269796108 13G  

     

    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

    (a)

     

     

    Amount beneficially owned:

     

    As of December 31, 2022, Mr. Tarriff beneficially owned 2,533,457 shares of the Issuer’s Common Stock consisting of (i) 353,788 shares of Common Stock owned directly by him, (ii) 176,361 shares of Common Stock held by Janney Montgomery Scott LLC CUST FBO Scott Tarriff IRA for the Benefit of Mr. Tarriff (the “IRA Trust”), of which Mr. Tarriff is a trustee and, as such, may be deemed to share voting and dispositive power with respect to all shares held by the IRA Trust, (iii) options to purchase 987,410 shares of Common Stock exercisable within 60 days of December 31, 2022, (iv) 23,275 shares of Common Stock underlying restricted stock units (“RSUs”) that will vest within 60 days of December 31, 2022 and (v) 992,623 shares of Common Stock held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the “Family Trust”) for the benefit of Mr. Tarriff’s spouse and three children, of which Mr. Graves is the trustee, and as such, while Mr. Tarriff may be deemed to share voting and dispositive power with respect to all shares held by the Family Trust, Mr. Tarriff disclaims beneficial ownership with respect to such shares in the Family Trust, except to the extent of his pecuniary interest therein. Mr. Tarriff’s beneficial ownership does not include 86,300 shares of Common Stock underlying performance-based restricted stock units that are subject to vesting on February 1, 2024 to the extent that certain performance objectives are achieved.

     

    As of December 31, 2022, Mr. Graves beneficially owned 1,117,363 shares of the Issuer’s Common Stock consisting of (i) 1,000 shares of Common Stock owned directly by him, (ii) options to purchase 123,740 shares of Common Stock exercisable within 60 days of December 31, 2022 and (iii) 992,623 shares of Common Stock held by the Family Trust for the benefit of Mr. Tarriff’s spouse and three children, of which Mr. Graves is the trustee. Mr. Graves disclaims any pecuniary interest with respect to such shares in the Family Trust.

     

      

     

     

    (b)

     

     

    Percent of class:

     

    For Mr. Tarriff: based on 13,016,645 shares of the Issuer’s Common Stock issued and outstanding as of December 31, 2022 (which does not include 4,552,730 treasury shares) as reported by the Issuer to the Reporting Person and assumes the exercise of 987,410 options held by Mr. Tarriff that are exercisable, and the vesting of 23,275 RSUs that are held Mr. Tarriff that will vest, within 60 days of December 31, 2022. As of December 31, 2022, the 2,533,457 shares of the Issuer’s Common Stock beneficially owned by Mr. Tarriff represented 18.06% of such shares outstanding.

     

    For the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016: based on 13,016,645 shares of the Issuer’s Common Stock issued and outstanding as of December 31, 2022 (which does not include 4,552,730 treasury shares) as reported by the Issuer to the Reporting Person. As of December 31, 2022, the 992,623 shares of the Issuer’s Common Stock beneficially owned by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 represented 7.63% of such shares outstanding.

     

    For Mr. Graves: based on 13,016,645 shares of the Issuer’s Common Stock issued and outstanding as of December 31, 2022 (which does not include 4,552,730 treasury shares) as reported by the Issuer to the Reporting Person and assumes the exercise of 123,740 options held by Mr. Graves that are exercisable within 60 days of December 31, 2022. As of December 31, 2022, the 1,117,363 shares of the Issuer’s Common Stock beneficially owned by Mr. Graves represented 8.50% of such shares outstanding.

     

    7

    7 
     

     

    CUSIP No. 269796108 13G  

     

      (c) Number of shares as to which the person has: 
        (i)

    Sole power to vote or to direct the vote:

     

    Scott Tarriff – 1,364,473

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 – 0

    Michael Graves – 124,740

     

     

     

     

     

     

     

    (ii)

     

     

     

    Shared power to vote or to direct the vote:

     

    Scott Tarriff – 1,168,984

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 – 992,623

    Michael Graves – 992,623 

     

     

     

     

     

     

     

    (iii)

     

     

     

    Sole power to dispose or to direct the disposition of:

     

    Scott Tarriff – 1,364,473

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 – 0

    Michael Graves – 124,740

     

     

     

     

     

     

     

    (iv)

     

     

     

    Shared power to dispose or to direct the disposition of:

     

    Scott Tarriff – 1,168,984

    Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 – 992,623

    Michael Graves – 992,623 

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable
     

    Item 7.

     

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    Not applicable
     
    Item 8. Identification and Classification of Members of the Group 

     

    Not applicable
     
    Item 9. Notice of Dissolution of Group.
    Not applicable
     
    Item 10. Certification
    Not applicable

     

     

    8 
     

     

    CUSIP No. 269796108 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      

    February 14, 2023

     

     
       
      By: /s/ Scott Tarriff
        Scott Tarriff
         
         
      Tarriff 2016 Generation Skipping Exempt Family Trust
    DTD 12/28/2016
         
      By: /s/ Michael Graves
      Name: Michael Graves
      Title: Trustee
         
         
      By: /s/ Michael Graves
        Michael Graves

     

    9 

     

    Get the next $EGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EGRX

    DatePrice TargetRatingAnalyst
    8/10/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    8/9/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    More analyst ratings

    $EGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Krawtschuk Christopher

    3 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

    11/19/24 7:59:53 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tarriff Scott covered exercise/tax liability with 2,119 shares, decreasing direct ownership by 0.46% to 460,621 units (SEC Form 4)

    4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

    3/1/24 4:40:02 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cahill Brian Joseph was granted 3,800 shares and covered exercise/tax liability with 1,589 shares, increasing direct ownership by 5% to 47,958 units (SEC Form 4)

    4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

    2/29/24 8:23:05 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eagle Pharmaceuticals Announces Divestiture of Barhemsys

    WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective option to manage this common complication. "This strategic divestitu

    1/14/26 10:21:32 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has adopted an amendment (the "Amendment") to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company's common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were

    10/30/25 6:50:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

    WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the "Annual Meeting") held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 1.   Election of Directors Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin

    10/21/25 4:05:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    SEC Filings

    View All

    SEC Form 15-12G filed by Eagle Pharmaceuticals Inc.

    15-12G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

    1/24/25 4:08:37 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Eagle Pharmaceuticals Inc.

    EFFECT - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

    12/10/24 12:15:03 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

    12/2/24 4:17:10 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eagle Pharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

    8/10/23 7:32:29 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

    8/9/23 10:15:46 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts resumed coverage on Eagle Pharma with a new price target

    RBC Capital Mkts resumed coverage of Eagle Pharma with a rating of Outperform and set a new price target of $52.00

    4/7/21 6:39:38 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Financials

    Live finance-specific insights

    View All

    Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has adopted an amendment (the "Amendment") to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company's common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were

    10/30/25 6:50:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

    3/21/25 4:30:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

    10/31/24 8:00:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

    WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the "Annual Meeting") held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 1.   Election of Directors Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin

    10/21/25 4:05:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

    WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has agreed to appoint Abhinav "Abi" Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders and serve on the Board's Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain's planned appointment, Eagle entered into a cooperation agreement (the "Agreement") with Nantahala Capital Management, LLC (together with its affiliates, "Nantahala"),

    8/28/25 7:30:40 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

    WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

    11/12/24 7:00:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

    11/14/24 11:34:47 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

    11/5/24 4:32:23 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

    10/31/24 1:36:40 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care